

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
 NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web  
 NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates  
 NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update  
 frequency  
 NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02  
 NEWS 6 Mar 08 Gene Names now available in BIOSIS  
 NEWS 7 Mar 22 TOXLIT no longer available  
 NEWS 8 Mar 22 TRCTHERMO no longer available  
 NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS  
 and USPATFULL  
 NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY  
 NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2  
 instead.  
 NEWS 12 Apr 08 "Ask CAS" for self-help around the clock  
 NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
 NEWS 14 Apr 09 ZDB will be removed from STN  
 NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and  
 IFIUDB  
 NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and  
 ZCAPLUS  
 NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
 NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available  
  
 NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
 CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
 AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
 NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS INTER General Internet Information  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
 specific topic.

All use of STN is subject to the provisions of the STN Customer  
 agreement. Please note that this agreement limits use to scientific  
 research. Use for software development or design or implementation  
 of commercial gateways or other similar uses is prohibited and may  
 result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:04:45 ON 24 MAY 2002

=> file medline, biosis, dgene, embase, jicst, japio, frosti, fsta, uspatful

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	0.42

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 15:05:32 ON 24 MAY 2002

FILE 'BIOSIS' ENTERED AT 15:05:32 ON 24 MAY 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'DGENE' ENTERED AT 15:05:32 ON 24 MAY 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 15:05:32 ON 24 MAY 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 15:05:32 ON 24 MAY 2002  
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'JAPIO' ENTERED AT 15:05:32 ON 24 MAY 2002  
COPYRIGHT (C) 2002 Japanese Patent Office (JPO)

FILE 'FROSTI' ENTERED AT 15:05:32 ON 24 MAY 2002  
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:05:32 ON 24 MAY 2002  
COPYRIGHT (C) 2002 International Food Information Service

FILE 'USPATFULL' ENTERED AT 15:05:32 ON 24 MAY 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s insulin ailment

L1            0 INSULIN AILMENT

=> s insulin

L2            630045 INSULIN

=> s l2 and ailment or disease

4 FILES SEARCHED...

L3            6519258 L2 AND AILMENT OR DISEASE

=> s non-peptidyl compound

L4            33 NON-PEPTIDYL COMPOUND

=> s l4 and method

L5            33 L4 AND METHOD

=> s l5 and l3

L6            26 L5 AND L3

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 26 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
TI Anti-obesity and insulin sensitizing effects of small molecule insulin  
receptor activators.

ACCESSION NUMBER: 2001:458806 BIOSIS  
DOCUMENT NUMBER: PREV200100458806  
TITLE: Anti-obesity and insulin sensitizing effects of small  
molecule insulin receptor activators.  
AUTHOR(S): Strowski, Mathias Z. (1); Air, Ellen; Salituro, Gino M.;  
Liu, Kun; Woods, Stephen C.; Zhang, Bei B.  
CORPORATE SOURCE: (1) Rahway, NJ USA  
SOURCE: Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp.  
A275. print.  
Meeting Info.: 61st Scientific Sessions of the American  
Diabetes Association Philadelphia, Pennsylvania, USA June  
22-26, 2001  
ISSN: 0012-1797.  
DOCUMENT TYPE: Conference  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L6 ANSWER 2 OF 26 USPATFULL  
TI Compounds and methods for modulating junctional adhesion  
molecule-mediated functions  
AB Methods for using modulating agents to enhance or inhibit junctional  
adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo  
and in vitro contexts are provided. The modulating agents comprise at  
least one JAM cell adhesion recognition sequence or an antibody or  
fragment thereof that specifically binds the JAM cell adhesion  
recognition sequence. Modulating agents may additionally comprise one  
or more cell adhesion recognition sequences recognized by other adhesion  
molecules. Such modulating agents may, but need not, be linked to a  
targeting agent, drug and/or support material.

ACCESSION NUMBER: 2002:116254 USPATFULL  
TITLE: Compounds and methods for modulating junctional  
adhesion molecule-mediated functions  
INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA  
Symonds, James Matthew, Ottawa, CANADA  
Gour, Barbara J., Kemptville, CANADA  
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, CANADA (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391855	B1	20020521
APPLICATION INFO.:	US 1999-324541		19990602 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Saunders, David		
ASSISTANT EXAMINER:	DeCloux, Amy		
LEGAL REPRESENTATIVE:	SEED Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	2338		

L6 ANSWER 3 OF 26 USPATFULL  
TI Piperidine compounds  
AB Novel compounds are described. The compounds generally comprise an  
acidic group, a basic group, a substituted amino or N-acyl and a group  
having an optionally hydroxylated alkane moiety. Pharmaceutical

compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:88641 USPATFULL  
TITLE: Piperidine compounds  
INVENTOR(S): Kim, Choung U., San Carlos, CA, United States  
Williams, Matthew A., Foster City, CA, United States  
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376674	B1	20020423
APPLICATION INFO.:	US 1999-376995		19990818 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-955564, filed on 17 Oct 1997, now patented, Pat. No. US 5994377 Continuation-in-part of Ser. No. US 1996-735285, filed on 21 Oct 1996, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28901P	19961021 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davis, Zinna Northington	
LEGAL REPRESENTATIVE:	Bosse, Mark L.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	4820	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 26 USPATFULL  
TI Biologically active compounds and methods of constructing and using the same  
AB A **method** of constructing biologically active compounds which mimic the biological activity of the biologically active protein block the activity of the biologically active protein is disclosed. A **method** of identifying specific and discrete portions of pathogen antigens which either serve as epitopes for neutralizing antibodies or which are involved in pathogen binding to host cell receptors is disclosed. A **method** of constructing biologically active compounds which compete with cellular receptors for binding to either biologically active proteins or pathogen antigens is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:81606 USPATFULL  
TITLE: Biologically active compounds and methods of constructing and using the same  
INVENTOR(S): Greene, Mark I., Penn Valley, PA, United States  
Williams, William V., Havertown, PA, United States  
Weiner, David B., Merion, PA, United States  
Cohen, Jeffrey A., Solon, OH, United States  
Kieber-Emmons, Thomas, Newtown Square, PA, United States  
Williams, Robert M., Fort Collins, CO, United States  
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania,  
Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	6372884	B1	20020416
APPLICATION INFO.:	US 1996-752816		19961121 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-940654, filed on 3 Sep 1992, now patented, Pat. No. US 5637677		
	Continuation-in-part of Ser. No. US 1991-702833, filed on 20 May 1991, now abandoned Continuation of Ser. No. US 1989-326328, filed on 21 Mar 1989, now abandoned		
	Continuation-in-part of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned Continuation-in-part of Ser. No. US 1990-462542, filed on 9 Jan 1990, now abandoned Division of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned Continuation-in-part of		
Ser.	No. US 1991-648303, filed on 25 Jan 1991, now		
abandoned	Continuation of Ser. No. US 1987-74264, filed on 16		
Jul	1987, now abandoned Continuation-in-part of Ser. No.		
US	1991-685881, filed on 15 Apr 1991, now abandoned Continuation of Ser. No. US 1990-574391, filed on 27 Aug 1990, now abandoned Continuation of Ser. No. US 1988-194026, filed on 13 May 1988, now patented, Pat. No. US 4962510 Continuation-in-part of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned Continuation-in-part of Ser. No. US 1990-583626, filed on 14 Sep 1990, now abandoned		

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Burke, Julie  
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP  
NUMBER OF CLAIMS: 2  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 43 Drawing Page(s)  
LINE COUNT: 2624  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 26 USPATFULL  
TI Process for determining the agonist or antagonist of galanin receptor (GALR3)  
AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2002:75211 USPATFULL  
TITLE: Process for determining the agonist or antagonist of galanin receptor (GALR3)  
INVENTOR(S): Bard, Jonathan A., Doylestown, PA, United States  
Borowsky, Beth, Montclair, NJ, United States  
Smith, Kelli E., Wayne, NJ, United States  
Branchek, Theresa A., Teaneck, NJ, United States  
Gerald, Christophe P. G., Ridgewood, NJ, United States

PATENT ASSIGNEE(S): Jones, Kenneth A., Bergenfield, NJ, United States  
Synaptic Pharmaceutical Corporation, Paramus, NJ,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6368812	B1	20020409
APPLICATION INFO.:	US 1998-58333		19980409 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1997-US18222, filed on 9 Oct 1997 Continuation-in-part of Ser. No. US 1997-900230, filed on 23 Jul 1997 Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, now abandoned Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, now abandoned Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Pak, Michael		
LEGAL REPRESENTATIVE:	White, John P., Cooper & Dunham LLP		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	5216		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L6 ANSWER 6 OF 26 USPATFULL  
TI Compounds and methods for modulating nonclassical cadherin-mediated  
functions  
AB Modulating agents for inhibiting or enhancing nonclassical cadherin  
mediated cell adhesion are provided. The modulating agents comprise one  
or more of: (a) a peptide sequence that is at least 50% identical to a  
nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a  
nonclassical cadherin CAR sequence; (c) a substance, such as an  
antibody  
or antigen-binding fragment thereof, that specifically binds a  
nonclassical cadherin CAR sequence; and/or (d) a polynucleotide  
encoding  
a polypeptide that comprises a nonclassical cadherin CAR sequence or  
analogue thereof. Methods for using such modulating agents for  
modulating nonclassical cadherin-mediated cell adhesion in a variety of  
contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:57757 USPATFULL  
TITLE: Compounds and methods for modulating nonclassical  
cadherin-mediated functions  
INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA  
Gour, Barbara J., Montreal, CANADA  
PATENT ASSIGNEE(S): Adherex Technologies, Ottawa, CANADA (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358920	B1	20020319
APPLICATION INFO.:	US 1998-187859		19981106 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-73040, filed on 5 May 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Allen, Marianne P.		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	20		

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 23 Drawing Page(s)  
LINE COUNT: 236  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 26 USPATFULL

TI Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

AB This invention provides methods of modifying feeding behavior, including

increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or

the Y5 receptor. One such compound has the structure: ##STR1##

In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:202393 USPATFULL

TITLE: Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

INVENTOR(S): Gerald, Christophe P. G., Ridgewood, NJ, United States  
Weinshank, Richard L., Teaneck, NJ, United States  
Walker, Mary W., Elmwood Park, NJ, United States

PATENT ASSIGNEE(S): Branchek, Theresa, Teaneck, NJ, United States  
Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316203	B1	20011113
APPLICATION INFO.:	US 1998-200673		19981125 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-566096, filed on 1 Dec 1995, now patented, Pat. No. US 5968819 Continuation-in-part of Ser. No. US 1994-349025, filed on 2 Dec 1994, now patented, Pat. No. US 5602024, issued on 11 Feb 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	White, John P. Cooper & Dunham LLP		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	45 Drawing Figure(s); 40 Drawing Page(s)		
LINE COUNT:	4363		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 26 USPATFULL

TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such

vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:158027 USPATFULL  
 TITLE: DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof  
 INVENTOR(S): Salon, John A., Montclair, NJ, United States  
 Laz, Thomas M., Parlin, NJ, United States  
 Nagorny, Raisa, Fair Lawn, NJ, United States  
 Wilson, Amy E., New York, NY, United States  
 PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ,  
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6291195	B1	20010918
APPLICATION INFO.:	US 2000-478602		20000106 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-224426, filed on 31 Dec 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Spector, Lorraine		
ASSISTANT EXAMINER:	O'Hara, Eileen B.		
LEGAL REPRESENTATIVE:	White, John P. Cooper & Dunham LLP		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	2920		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 26 USPATFULL

TI DNA encoding galanin GALR3 receptors and uses thereof  
 AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA

encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:152696 USPATFULL  
 TITLE: DNA encoding galanin GALR3 receptors and uses thereof  
 INVENTOR(S): Bard, Jonathan A., Doylestown, PA, United States  
 Borowsky, Beth, Montclair, NJ, United States  
 Smith, Kelli E., Wayne, NJ, United States  
 Brancheck, Theresa A., Teaneck, NJ, United States  
 Gerald, Christophe P. G., Ridgewood, NJ, United States  
 Jones, Kenneth A., Bergenfield, NJ, United States  
 PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ,  
 United States (U.S. corporation)



	NUMBER	KIND	DATE
PATENT INFORMATION:	6287788	B1	20010911
APPLICATION INFO.:	US 1998-199737		19981125 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-US18222, filed on 9 Oct 1997 Continuation-in-part of Ser. No. US 1997-900230, filed on 23 Jul 1997 Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, now abandoned Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, now abandoned Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Pak, Michael		
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	4441		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L6 ANSWER 10 OF 26 USPATFULL  
 TI DNA ENCODING GALANIN GALR3 RECEPTORS AND USES THEREOF  
 AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding  
 a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2001:119145 USPATFULL  
 TITLE: DNA ENCODING GALANIN GALR3 RECEPTORS AND USES THEREOF  
 INVENTOR(S): BARD, JONATHAN A., DOLYTOWN, PA, United States  
 BOROWSKY, BETH, MONTCLAIR, NJ, United States  
 SMITH, KELLI E., WAYNE, NJ, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001009766	A1	20010726
	US 6329197	B2	20011211
APPLICATION INFO.:	US 1997-900230	A1	19970723 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	COOPER & DUNHAM, 1185 AVE OF THE AMERICAS, NEW YORK, NY, 10036		
NUMBER OF CLAIMS:	211		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Page(s)		
LINE COUNT:	4388		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L6 ANSWER 11 OF 26 USPATFULL

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:97888 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, New Zealand  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, United Kingdom  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251865	B1	20010626
APPLICATION INFO.:	US 1998-52888		19980331 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David		
LEGAL REPRESENTATIVE:	Hasak, Janet E.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	4925		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 26 USPATFULL  
TI Peptides and peptidomimetics with structural similarity to human P53 that activate P53 function  
AB The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and to select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:86587 USPATFULL  
TITLE: Peptides and peptidomimetics with structural similarity to human P53 that activate P53 function  
INVENTOR(S): Halazonetis, Thanos, Philadelphia, PA, United States  
Hartwig, Wolfgang, Stamford, CT, United States  
PATENT ASSIGNEE(S): Bayer Corporation, Westhaver, CT, United States (U.S. corporation)  
The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6245886	B1	20010612
	WO 9625434		19960822
APPLICATION INFO.:	US 1997-894327		19971204 (8)
	WO 1996-US1535		19960216
			19971204 PCT 371 date
			19971204 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-392542, filed		

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Huff, Sheela  
 LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.  
 NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1305  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 26 USPATFULL

TI Compounds and methods for synthesis and therapy  
 AB Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:63718 USPATFULL  
 TITLE: Compounds and methods for synthesis and therapy  
 INVENTOR(S): Bischofberger, Norbert W., San Carlos, CA, United States  
 Kim, Choung U., San Carlos, CA, United States  
 Lew, Willard, San Mateo, CA, United States  
 Liu, Hongtao, Foster City, CA, United States  
 Williams, Matthew A., Foster City, CA, United States  
 PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225341	B1	20010501
APPLICATION INFO.:	US 1999-288091		19990408 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-606624, filed on 26 Feb 1996, now patented, Pat. No. US 5952375		
	Continuation-in-part of Ser. No. US 1995-580567, filed on 29 Dec 1995, now abandoned		
	Continuation-in-part of Ser. No. US 1995-476946, filed on 6 Jun 1995, now patented, Pat. No. US 5866601		
	Continuation-in-part of Ser. No. US 1995-395245, filed on 27 Feb 1995, now abandoned		

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Lambkin, Deborah C.  
 LEGAL REPRESENTATIVE: Bosse, Mark L.  
 NUMBER OF CLAIMS: 2  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)  
 LINE COUNT: 11195  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 26 USPATFULL

TI DNA encoding SNORF25 receptor  
 AB This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides

complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:59682 USPATFULL  
 TITLE: DNA encoding SNORF25 receptor  
 INVENTOR(S): Bonini, James A., Oakland, NJ, United States  
 Borowsky, Beth E., Montclair, NJ, United States  
 Adham, Nika, Ridgewood, NJ, United States  
 Boyle, Noel, Cliffside Park, NJ, United States  
 Thompson, Thelma O., Passaic Park, NJ, United States  
 PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ,  
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221660	B1	20010424
APPLICATION INFO.:	US 1999-387699		19990813 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-255376, filed on 22 Feb 1999		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spector, Lorraine		
ASSISTANT EXAMINER:	O'Hara, Eileen B.		
LEGAL REPRESENTATIVE:	White, John P. Cooper & Dunham LLP		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2877		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 26 USPATFULL  
 TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof  
 AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:59638 USPATFULL  
 TITLE: DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof  
 INVENTOR(S): Salon, John A., Montclair, NJ, United States  
 Laz, Thomas M., Parlin, NJ, United States  
 Nagorny, Raisa, Fair Lawn, NJ, United States  
 Wilson, Amy E., New York, NY, United States  
 PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ,  
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221616	B1	20010424
APPLICATION INFO.:	US 2000-478601		20000106 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-224426, filed on 31 Dec 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spector, Lorraine		
ASSISTANT EXAMINER:	O'Hara, Eileen B.		
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	2882		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 26 USPATFULL  
 TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof  
 AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:59635 USPATFULL  
 TITLE: DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof  
 INVENTOR(S): Salon, John A., Montclair, NJ, United States  
 Laz, Thomas M., Parlin, NJ, United States  
 Nagorny, Raisa, Fair Lawn, NJ, United States  
 Wilson, Amy E., New York, NY, United States  
 PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221613	B1	20010424
APPLICATION INFO.:	US 1998-224426		19981231 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spector, Lorraine		
ASSISTANT EXAMINER:	O'Hara, Eileen B.		
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	2913		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 26 USPATFULL  
 TI Synthesis and use of .alpha.-ketoamide derivatives and arrays  
 AB The invention is based on new methods for making and using compounds and

by arrays of novel .alpha.-ketoamides, and the arrays and compounds made  
these methods. These novel compounds are potential inhibitors of  
proteolytic enzymes, particularly cysteine proteases such as cruzain.  
Application of the new methods has led to the identification of a  
number of new inhibitors, from amongst an array of about 38,000  
.alpha.-ketoamide derivatives, having specific activity against three  
cysteine proteases: cruzain, papain, and cathepsin B. These compounds  
and other compounds identified by the methods described herein can be  
useful, for example, in developing pharmaceutical agents for the  
treatment of diseases (e.g., Chagas' **disease**) associated with these  
proteases. Although the disclosed compounds have specific activity for  
cruzain, papain, cathepsin B, the methods described herein can also be  
used to identify inhibitors of other proteases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:150348 USPATFULL  
TITLE: Synthesis and use of .alpha.-ketoamide derivatives and  
arrays  
INVENTOR(S): Baldino, Carmen M., Lexington, MA, United States  
Coffen, David L., Cambridge, MA, United States  
Chipman, Stewart D., Reading, MA, United States  
Cheng, Hong, Brighton, MA, United States  
PATENT ASSIGNEE(S): ArQule, Inc., Medford, MA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6143931		20001107
APPLICATION INFO.:	US 1998-61752		19980416 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-44768P	19970416 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lukton, David	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	11	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	954	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 26 USPATFULL

TI Compounds and methods for modulating tissue permeability  
AB Methods for using modulating agents to enhance or inhibit  
occludin-mediated cell adhesion in a variety of in vivo and in vitro  
contexts are provided. Within certain embodiments, the modulating  
agents may be used to increase vasopermeability. The modulating agents  
comprise at least one occludin cell adhesion recognition sequence or an antibody  
or fragment thereof that specifically binds the occludin cell adhesion  
recognition sequence. Modulating agents may additionally comprise one  
or more cell adhesion recognition sequences recognized by other adhesion  
molecules. Such modulating agents may, but need not, be linked to a  
targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:113775 USPATFULL

TITLE: Compounds and methods for modulating tissue permeability  
INVENTOR(S): Laschuk, Orest W., Westmount, Canada  
Symonds, James Matthew, Ottawa, Canada  
Gour, Barbara J., Kemptville, Canada  
PATENT ASSIGNEE(S): Adherex Technologies Inc., Ottawa, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6110747		20000829
APPLICATION INFO.:	US 1998-222373		19981229 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-1511, filed on 31 Dec 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davenport, Avis M.		
LEGAL REPRESENTATIVE:	Seed IP Law Group PLLC		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2887		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 26 USPATFULL

TI Piperidine compounds

AB Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:155760 USPATFULL  
TITLE: Piperidine compounds  
INVENTOR(S): Kim, Choung U., San Carlos, CA, United States  
Williams, Matthew A., Foster City, CA, United States  
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994377		19991130
APPLICATION INFO.:	US 1997-955564		19971017 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-735385, filed on 21 Oct 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28901P	19961021 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Davis, Zinna Northington	
LEGAL REPRESENTATIVE:	Bosse, Mark L.	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4903	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 26 USPATFULL  
TI Methods of modifying feeding behavior compounds useful in such methods  
and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY  
receptor Y5  
AB This invention provides methods of modifying feeding behavior,  
including

increasing or decreasing food consumption, e.g., in connection with  
treating obesity, bulimia or anorexia. These methods involve  
administration of compounds that are selective agonists or antagonists  
for the Y5 receptor. One such compound has the structure: ##STR1## In  
addition, this invention provides an isolated nucleic acid molecule  
encoding a Y5 receptor, an isolated Y5 receptor protein, vectors  
comprising an isolated nucleic acid molecule encoding a Y5 receptor,  
cells comprising such vectors, antibodies directed to the Y5 receptor,  
nucleic acid probes useful for detecting nucleic acid encoding Y5  
receptors, antisense oligonucleotides complementary to any unique  
sequences of a nucleic acid molecule which encodes a Y5 receptor, and  
nonhuman transgenic animals which express DNA encoding a normal or a  
mutant Y5 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:151023 USPATFULL  
TITLE: Methods of modifying feeding behavior compounds useful  
in such methods and DNA encoding a hypothalamic

atypical

neuropeptide Y/peptide YY receptor Y5  
INVENTOR(S): Gerald, Christophe P. G., Ridgewood, NJ, United States  
Weinshank, Richard L., Teaneck, NJ, United States  
Walker, Mary W., Elmwood Park, NJ, United States  
Branchek, Theresa, Teaneck, NJ, United States  
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5989920		19991123
APPLICATION INFO.:	US 1996-668650		19960604 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-566096, filed on 1 Dec 1995 which is a continuation-in-part of Ser. No. US 1994-349025, filed on 2 Dec 1994, now patented, Pat. No. US 5602024		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Caputa, Anthony C.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	47 Drawing Figure(s); 42 Drawing Page(s)		
LINE COUNT:	5364		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 26 USPATFULL  
TI **Method** of identifying ligands which bind recombinant galanin  
receptor (GALR2)  
AB This invention provides an isolated nucleic acid encoding a mammalian  
galanin receptor, an isolated galanin receptor protein, vectors  
comprising an isolated nucleic acid encoding a galanin receptor, cells  
comprising such vectors, antibodies directed to the galanin receptor,  
nucleic acid probes useful for detecting nucleic acid encoding galanin  
receptors, antisense oligonucleotides complementary to unique sequences  
of a nucleic acid encoding a galanin receptor, nonhuman transgenic  
animals which express DNA encoding a normal or a mutant galanin  
receptor, as well as methods of determining binding of compounds to the



galanin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:132514 USPATFULL

TITLE: Method of identifying ligands which bind recombinant galanin receptor (GALR2)

INVENTOR(S): Smith, Kelli E., Wayne, NJ, United States  
Gerald, Christophe P. G., Ridgewood, NJ, United States  
Weinshank, Richard L., Teaneck, NJ, United States  
Linemeyer, David, Westfield, NJ, United States  
Branchek, Theresa, Teaneck, NJ, United States  
Forray, Carlos, Paramus, NJ, United States

PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972624		19991026
APPLICATION INFO.:	US 1996-626685		19960401 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-590494, filed on 24 Jan 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Pak, Michael		
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	2695		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 26 USPATFULL

TI DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

AB This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or

the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:128435 USPATFULL

TITLE: DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

INVENTOR(S): Gerald, Christophe P. G., Ridgewood, NJ, United States  
Weinshank, Richard L., Teaneck, NJ, United States  
Walker, Mary W., Elmwood Park, NJ, United States  
Branchek, Theresa, Teaneck, NJ, United States  
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ,  
United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5968819 19991019  
 APPLICATION INFO.: US 1995-566096 19951201 (8)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. 1994-349025, filed  
 on 2 Dec 1994, now patented, Pat. No. US 5602024

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Duffy, Patricia  
 ASSISTANT EXAMINER: Gucker, Stephen  
 LEGAL REPRESENTATIVE: White, John P. Cooper & Dunham Llp  
 NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 45 Drawing Figure(s); 40 Drawing Page(s)  
 LINE COUNT: 4657  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 26 USPATFULL

TI Compounds and methods for synthesis and therapy  
 AB Novel compounds are described. The compounds generally comprise an  
 acidic group, a basic group, a substituted amino or N-acyl and a group  
 having an optionally hydroxylated alkane moiety. Pharmaceutical  
 compositions comprising the inhibitors of the invention are also  
 described. Methods of inhibiting neuraminidase in samples suspected of  
 containing neuraminidase are also described. Antigenic materials,  
 polymers, antibodies, conjugates of the compounds of the invention with  
 labels, and assay methods for detecting neuraminidase activity are also  
 described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:110364 USPATFULL  
 TITLE: Compounds and methods for synthesis and therapy  
 INVENTOR(S): Bischofberger, Norbert W., San Carlos, CA, United  
 States  
 Kim, Choung U., San Carlos, CA, United States  
 Lew, Willard, San Mateo, CA, United States  
 Liu, Hongtao, Foster City, CA, United States  
 Williams, Matthew A., Foster City, CA, United States  
 PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5952375		19990914
APPLICATION INFO.:	US 1996-606624		19960226 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-580567, filed on 29 Dec 1995, now abandoned which is a continuation-in-part of Ser. No. US 1995-476946, filed on 6 Jun 1995, now patented, Pat. No. US 5866601 which is a continuation-in-part of Ser. No. US 1995-395245, filed on 27 Feb 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Bosse, Mark L.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	10750		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L6 ANSWER 24 OF 26 USPATFULL

TI Enhancing the sensitivity of immunoassay procedures by use of  
 antibodies  
 directed to the product of a reaction between probe labels and assay  
 substrates

AB The subject invention provides an antibody which specifically binds to the product of a reaction between a labeling substance and a substrate. The subject invention also provides a method of making an immunogen used to produce the antibody of the subject invention. The invention further provides methods of using the subject antibody for detecting an antigen of interest in a sample, for example, detecting a protein comprising an amino acid sequence of interest and detecting a nucleic acid molecule comprising a nucleic acid sequence of interest, detecting a polypeptide such as those expressed by infectious agents, fungi or parasites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:81724 USPATFULL

TITLE: Enhancing the sensitivity of immunoassay procedures by use of antibodies directed to the product of a

reaction

between probe labels and assay substrates

INVENTOR(S):

Erlanger, Bernard F., Whitestone, NY, United States

Chen, Bi-Xing, New York, NY, United States

PATENT ASSIGNEE(S):

The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5925532		19990720
APPLICATION INFO.:	US 1997-898583		19970722 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1996-US3549, filed on 14 Mar 1996 which is a continuation-in-part of Ser. No. US 1995-403649, filed on 14 Mar 1995, now		

patented,

Pat. No. US 5650284

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Scheiner, Toni R.

LEGAL REPRESENTATIVE:

White, John P. Cooper & Dumham LLP

NUMBER OF CLAIMS:

11

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

25 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT:

1245

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 26 USPATFULL

TI Carbocyclic compounds

AB Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:65265 USPATFULL

TITLE: Carbocyclic compounds

INVENTOR(S):

Bischofberger, Norbert W., San Carlos, CA, United States

Kim, Choung U., San Carlos, CA, United States

Lew, Willard, San Mateo, CA, United States

Liu, Hongtao, Foster City, CA, United States

Williams, Matthew A., Foster City, CA, United States

PATENT ASSIGNEE(S):

Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5763483		19980609
APPLICATION INFO.:	US 1996-774345		19961227 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-9306P	19951229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Daus, Donald G.	
LEGAL REPRESENTATIVE:	Bosse, Mark L.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5694	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 26 USPATFULL

TI Biologically active compounds and methods of constructing and using the same

AB A **method** of constructing biologically active compounds which mimic the biological activity of the biologically active protein or which block the activity of the biologically active protein is disclosed. A **method** of identifying specific and discrete portions of pathogen antigens which either serve as epitopes for neutralizing antibodies or which are involved in pathogen binding to host cell receptors is disclosed. A **method** of constructing biologically active compounds which compete with cellular receptors for binding to either biologically active proteins or pathogen antigens is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:49724 USPATFULL

TITLE: Biologically active compounds and methods of constructing and using the same

INVENTOR(S): Greene, Mark I., Penn Valley, PA, United States  
Williams, William V., Havertown, PA, United States  
Weiner, David B., Merion, PA, United States  
Cohen, Jeffrey A., Bala Cynwyd, PA, United States  
Kieber-Emmons, Thomas, Newtown Square, PA, United States

PATENT ASSIGNEE(S): Williams, Robert M., Fort Collins, CO, United States  
The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)  
Colorado State University, Fort Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5637677		19970610
APPLICATION INFO.:	US 1992-940654		19920903 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-702833, filed on 20 May 1991, now abandoned which is a continuation of Ser. No. US 1989-326328, filed on 21 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned And a continuation-in-part of Ser. No. US 1990-462542, filed on 9 Jan 1990, now abandoned which is a division of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned And a continuation-in-part of Ser. No. US 1991-648303, filed on 25 Jan 1991, now abandoned which		

is a continuation of Ser. No. US 1987-74264, filed on  
16 Jul 1987, now abandoned And a continuation-in-part  
of Ser. No. US 1991-685881, filed on 15 Apr 1991, now  
abandoned which is a continuation of Ser. No. US  
1990-574391, filed on 27 Aug 1990, now abandoned which  
is a continuation of Ser. No. US 1988-194026, filed on  
13 May 1988, now abandoned which is a  
continuation-in-part of Ser. No. US 1987-74264, filed  
on 16 Jul 1987, now abandoned And a  
continuation-in-part of Ser. No. US 1990-583626, filed  
on 14 Sep 1990, now abandoned

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Cunningham, Thomas M.  
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris  
NUMBER OF CLAIMS: 35  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 43 Drawing Page(s)  
LINE COUNT: 2862  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.